- Breaking News San Mateo County ninth-graders struggle to stay fit
- Breaking News Food and wine events
- Breaking News Ask Amy: What To Do When the Doctor Isn t in the House
- Breaking News Ed Blonz: Keep your diet normal pre-surgery
NOVO NORDISK: EU approval of NovoNorm, Novo Nordisk's new oral treatment for Type 2 diabetes.
0 Comments | M2 Presswire, August, 1998
M2 PRESSWIRE-17 August 1998-NOVO NORDISK: EU approval of NovoNorm, Novo Nordisk's new oral treatment for Type 2 diabetes (C)1994-98 M2 COMMUNICATIONS LTD RDATE:170898 Novo Nordisk A/S (NYSE:NVO) today announced that the European Commission has approved NovoNorm (repaglinide - Prandin in the US).
NovoNorm belongs to a new class of oral anti-diabetic agents for the treatment of Type 2 diabetes. Lars Rebien Sorensen, Corporate Executive Vice President, head of Health Care at Novo Nordisk said, "We are extremely pleased that the European Commission has approved NovoNorm. We believe that NovoNorm with its unique meal related dosing concept will be seen by people with Type 2 diabetes as a therapeutic step forward compared to other oral anti-diabetic drugs."...
- Getting to the root of beautiful hair: shiny, silky hair begins with a healthy scalp - includes list of resources and a recipe for an herbal scalp tonic
- Industry Experts Launch Money Management Resources to Help People Overcome Debt and Learn Proper Money Management Practices
- Made from scratch: When Honda built a plant in Alabama it also built a workforce-using local workers who had no experience in making cars - Recruitment & Hiring
- Portfolio forecasting tools: what you need to know
- A multi-class SVM classifier utilizing binary decision tree
- Why fly solo when an executive assistant can accelerate your CLNC® business?
- Banking technology, technological learning and competition: comparative case studies in Thai banking
- Building a nursing portfolio